Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Follow-up for human papillomavirus-related oropharynx cancer concentrated on unequal symptom change (FOCUS): Prospective patient-reported outcome collection.
Edwards DM, Gharzai LA, Wang W, Mayo C, Suresh K, Schipper M, Evans JR, Malloy K, Chinn SB, Prince M, Spector M, Shuman A, Stucken C, Swiecicki PL, Worden F, Jarema J, Henderson C, Kovach A, Brenner C, Shah JL, Mierzwa ML, Casper K. Edwards DM, et al. Among authors: malloy k. Head Neck. 2024 Apr 29. doi: 10.1002/hed.27778. Online ahead of print. Head Neck. 2024. PMID: 38680087
A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer.
Swiecicki PL, Zhao L, Belile E, Sacco AG, Chepeha DB, Dobrosotskaya I, Spector M, Shuman A, Malloy K, Moyer J, McKean E, McLean S, Wolf GT, Eisbruch A, Prince M, Bradford C, Carey T, Worden FP. Swiecicki PL, et al. Among authors: malloy k. Invest New Drugs. 2015 Dec;33(6):1248-56. doi: 10.1007/s10637-015-0293-8. Epub 2015 Oct 10. Invest New Drugs. 2015. PMID: 26453566 Clinical Trial.
Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation.
Samuels SE, Tao Y, Lyden T, Haxer M, Spector M, Malloy KM, Prince ME, Bradford CR, Worden FP, Schipper M, Eisbruch A. Samuels SE, et al. Oral Oncol. 2016 Mar;54:68-74. doi: 10.1016/j.oraloncology.2015.12.001. Epub 2016 Jan 6. Oral Oncol. 2016. PMID: 26776757 Free PMC article. Clinical Trial.
A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.
Swiecicki PL, Bellile E, Sacco AG, Pearson AT, Taylor JM, Jackson TL, Chepeha DB, Spector ME, Shuman A, Malloy K, Moyer J, McKean E, McLean S, Sukari A, Wolf GT, Eisbruch A, Prince M, Bradford C, Carey TE, Wang S, Nör JE, Worden FP. Swiecicki PL, et al. Among authors: malloy k. Invest New Drugs. 2016 Aug;34(4):481-9. doi: 10.1007/s10637-016-0364-5. Epub 2016 May 26. Invest New Drugs. 2016. PMID: 27225873 Free PMC article. Clinical Trial.
Predictors of severe long-term toxicity after re-irradiation for head and neck cancer.
Lee JY, Suresh K, Nguyen R, Sapir E, Dow JS, Arnould GS, Worden FP, Spector ME, Prince ME, McLean SA, Shuman AG, Malloy KM, Casper K, Bradford CR, Schipper MJ, Eisbruch A. Lee JY, et al. Among authors: malloy km. Oral Oncol. 2016 Sep;60:32-40. doi: 10.1016/j.oraloncology.2016.06.017. Epub 2016 Jul 5. Oral Oncol. 2016. PMID: 27531870
E6 and E7 Antibody Levels Are Potential Biomarkers of Recurrence in Patients with Advanced-Stage Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma.
Spector ME, Sacco AG, Bellile E, Taylor JMG, Jones T, Sun K, Brown WC, Birkeland AC, Bradford CR, Wolf GT, Prince ME, Moyer JS, Malloy K, Swiecicki P, Eisbruch A, McHugh JB, Chepeha DB, Rozek L, Worden FP. Spector ME, et al. Among authors: malloy k. Clin Cancer Res. 2017 Jun 1;23(11):2723-2729. doi: 10.1158/1078-0432.CCR-16-1617. Epub 2016 Nov 21. Clin Cancer Res. 2017. PMID: 27872102 Free PMC article.
231 results